Abstract:OBJECTIVES/GOALS: To identify the role of sialoglycans in the mechanisms underlying cancer-associated fibroblast-derived exosomes (CAFEX) immuno-regulatory properties. The central hypothesis is that CAFEX manipulates the immune response to allow immunoevasion and glycomic approaches can identify the signaling factors involved. METHODS/STUDY POPULATION: Cancer associated fibroblasts (CAFs) were isolated from primary head and neck tumors, expanded, characterized and cryopreserved prior to experimentation and isolation of CAFEX. Sialoglycan expression was determined using lectin-specific staining of cells and bead-captured CAFEX in combination with flow cytometry analysis. Siglec expression and expression of M2-macrophage markers were also determined by flow cytometry analysis and cytokine bead arrays. Inhibition studies involved either the enzymatic removal of cell-surface sialoglycans or alternatively, a specific small molecule analog inhibitor of sialoglycan transferases. RESULTS/ANTICIPATED RESULTS: Both CAFs and CAFEX expressed abundant levels of cell-surface sialoglycans. CAFEX induced an M2-macrophage phenotype in primary monocytes, based on surface marker expression and cytokine secretion profiles. The induction of the M2 phenotype in macrophages was attenuated upon the removal of sialoglycans from the surface of CAFEX either by enzymatic removal or via a small molecule inhibitor. CAFEX were also able to directly bind members of the Siglec family, which are sialoglycan specific lectin receptors expressed on immune cells, including macrophages. DISCUSSION/SIGNIFICANCE: Collectively, these studies suggest that surface presentation of sialoglycans by CAFEX may induce an immunosuppressive phenotype in monocytes/macrophages. Consequently, this may be a novel mechanism by which cells within the tumor bed facilitate immunoevasion during tumor progression.

Engagement of sialylated glycans with Siglec receptors on suppressive myeloid cells inhibits anticancer immunity via CCL2

Siglec Receptors Modulate Dendritic Cell Activation and Antigen Presentation to T Cells in Cancer

Targeting cancer glycosylation repolarizes tumor-associated macrophages allowing effective immune checkpoint blockade

Sialic Acids on Tumor Cells Modulate IgA Therapy by Neutrophils via Inhibitory Receptors Siglec-7 and Siglec-9

Targeting stromal cell sialylation reverses T cell-mediated immunosuppression in the tumor microenvironment

Disruption of the sialic acid/Siglec-9 axis improves antibody-mediated neutrophil cytotoxicity towards tumor cells

Cancer-derived sialylated IgG promotes tumor immune escape by binding to Siglecs on effector T cells

Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy

Glioma-Associated Sialoglycans Drive the Immune Suppressive Phenotype and Function of Myeloid Cells

Sialylated IgG in epithelial cancers inhibits antitumor function of T cells via Siglec-7.

Modulation of Siglec-7 Signaling Via In Situ-Created High-Affinity cis -Ligands

Sialic acid and Siglec receptors in tumor immunity and immunotherapy

Targeting Siglec–Sialylated MUC1 Immune Axis in Cancer

405 Role of Glycans in Cancer Associated Fibroblast-Derived Exosome Immunoregulation

Sialylated glycoproteins suppress immune cell killing by binding to Siglec-7 and Siglec-9 in prostate cancer

The sialic acid-Siglec immune checkpoint: an opportunity to enhance immune responses and therapy effectiveness in melanoma

The Potential of Siglecs and Sialic Acids as Biomarkers and Therapeutic Targets in Tumor Immunotherapy

Tumor sialylation controls effective anti-cancer immunity in breast cancer

Tumor-associated carbohydrates and immunomodulatory lectins as targets for cancer immunotherapy

Installation of High-Affinity Siglec-1 Ligand on Tumor Surface for Macrophage-Engaged Tumor Suppression.

Glycosylation of Siglec15 promotes immunoescape and tumor growth